Orthostatic intolerance

Displaying 4 studies

  • Natural History Study of Synucleinopathies Rochester, MN

    Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control of movement or cognition. Patients with synucleinopathies and signs of CNS-deficits are frequently diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA). However, accumulation of ...

  • A Study to Evaluate the Effectiveness of Intravenous Iron Sucrose in Patients with Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) Rochester, MN

    This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).

  • A Study Using A Motion Device to Estimate Sleep Timing and Duration in Patients with Autonomic Dysfunction Rochester, MN

    The purpose of this study is to gain a better understanding of the sleep quality and fatigue complaints of adolescent orthostatic intolerance (OI) and postural orthostatic tachycardia syndrome (POTS) patients by objectively measuring sleep duration and timing with actigraphy. Sleep questionnaire will be administered to assess subjective sleep complaints and correlate them with objective findings.

  • 3,4-diaminopyridine (3,4-DAP) use in Patients with Orthostatic Hypotension and Postural Tachycardia Syndrome Rochester, MN

    If the efficacy of 3,4-diaminopyridine (3,4-DAP) can be demonstrated in this study, the use of 3,4-DAP alone and in combination with other agents such as pyridostigmine and L-DOPS would be further evaluated in a double-blind randomized placebo-controlled cross-over study


Mayo Clinic Footer